GlassScriptPhysician profile
Robert Hutchins
NPI 1144263476
$5,164.13
in general payments reported to CMS, 2019-2025
17 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $254 · 2021: $191 · 2022: $905 · 2023: $1,339 · 2024: $1,277 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,785.56 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $718.55 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $474.23 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $404.92 | 2023-2025 | Izervay |
| Genentech USA, INC. | $381.81 | 2022-2025 | Vabysmo |
| Eyepoint US, INC. | $348.54 | 2020-2023 | |
| Abbvie INC. | $239.97 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $205.13 | 2019-2023 | |
| Alcon Vision LLC | $192.37 | 2019-2025 | Rocklatan |
| Astellas US LLC | $135.72 | 2024 | Izervay |
| Regeneron Pharmaceuticals, INC. | $73.94 | 2024 | Eylea Hd, Eylea |
| Biogen, INC. | $67.58 | 2022-2023 | |
| Dutch Ophthalmic, USA | $66.61 | 2025 | Eva, Combined Machine, Tissueblue |
| Ani Pharmaceuticals, INC. | $27.46 | 2025 | Yutiq |
| Amgen INC. | $14.92 | 2025 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $14.14 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hutchins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.